September 2026: FDA cleared Biolinq Shine needle-free glucose sensor for OTC sale
Biolinq said on September 24, 2026, that the FDA had cleared its Shine forearm glucose sensor for sale without a prescription to adults 22 and older who do not use insulin.
Pulse, covering wearables and health sensors
Published , 2 min read
22+minimum age for over-the-counter Biolinq Shine
This is a look back at an event from . We wrote it on November 16, 2026, from the sources listed at the end.
What to know
- Biolinq announced FDA 510(k) clearance for over-the-counter sale of Biolinq Shine on September 24, 2026.
- The cleared use is adults 22 and older who are not on insulin, and the device shows glucose ranges, not numbers for dosing decisions.
- Shine first reached the market through an FDA De Novo authorization in September 2025 for adults with type 2 diabetes not on insulin.
Biolinq, a San Diego sensor maker, said on September 24, 2026, that the US Food and Drug Administration had granted 510(k) clearance for over-the-counter sale of Biolinq Shine, a glucose sensor worn on the forearm. The clearance means people can buy it without a prescription. We did not cover the news at the time; this look back fills that gap.
According to the company's release, the cleared use is adults 22 and older who are not on insulin. Healio, which reported the clearance on October 2, gave the same age limit and noted that the wording does not require a diabetes diagnosis.
How Shine differs from other glucose sensors
Most continuous glucose monitors (CGMs) push a thin filament under the skin with a spring-loaded needle and send readings to a phone. Biolinq says Shine uses semiconductor microsensors that sit just below the skin's surface, so no needle is needed to place it. Fierce Biotech reported in 2025 that the sensors sit up to 20 times shallower than filament-based CGMs. MedTech Dive described the same part as an array of microneedles; we use the company's term, microsensors.
Shine has its own small display. A color-coded light shows whether glucose is in, above or below a target range, so the wearer does not need a phone. An optional app adds how meals, movement and rest relate to glucose, and the device also tracks activity and sleep. For a primer on how standard CGMs read interstitial fluid, see how continuous glucose monitors work.
Shine does not show numbers meant for treatment. The release says it gives glucose range information for general awareness of patterns and trends, and is not meant for acute medical decisions such as insulin dosing or changing medication.
From prescription to the shelf
Shine first reached the market through a De Novo authorization in September 2025, which MedTech Dive and Fierce Biotech reported was for people with type 2 diabetes who do not depend on insulin. The 2026 clearance uses the 510(k) pathway, which compares a device to one already on the market; our explainer on FDA clearance, approval and De Novo sets out the difference.
Biolinq raised $100 million in a Series C round led by Alpha Wave in April 2025, according to Fierce Biotech. Rich Yang is chief executive. Fierce reported the company is also developing sensors for ketones and lactate; the clearances cover glucose only.
None of the sources we read gave Shine's price, wear time, launch date, store availability or accuracy data. The release did not include clinical study figures.
Where it fits
Shine joins a group of glucose wearables aimed at people who are not on insulin. Dexcom's CONNECT trial tested CGM use in type 2 diabetes without insulin, and Abbott's Libre Duo adds ketones to a glucose sensor. Outside the US, Huawei has put a glucose monitor in its Sense G1.
Why it matters
The clearance puts a needle-free glucose sensor on sale without a prescription, widening the over-the-counter market beyond filament sensors to a design that shows ranges on the device itself instead of numbers on a phone. Biolinq calls Shine the first needle-free wearable to track glucose, activity and sleep in one device.
This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.
Sources
- Biolinq Shine Receives FDA 510(k) Clearance for Over-the-Counter Use, Biolinq via GlobeNewswire, September 24, 2026
- FDA grants 510(k) clearance for OTC sale of needle-free CGM, Healio, October 2, 2026
- Biolinq gets FDA de novo nod for intradermal glucose sensor, MedTech Dive, September 26, 2025
- Biolinq's color-coded glucose sensor patch nets FDA clearance, Fierce Biotech, 2025
Glucose and metabolic techFDA and health regulationWearablesDigital health and AI in care
Written by an AI correspondent under standards set by editor Jacob Knight. Spotted an error? Tell us and we will fix it.